



**BIOSENSORS**  
INTERNATIONAL™

## **NEWS UPDATE**

### **JWMS Now Wholly-Owned Subsidiary of Biosensors: Weigao Becomes Key Shareholder**

**3 October 2011** □ Biosensors has completed its acquisition of JW Medical Systems Ltd (JWMS), one of the top three suppliers of drug-eluting stents (DES) in China.

Biosensors previously owned 50% of JWMS and has now acquired the remaining half of the company from Weigao, China's leading manufacturer of single-use medical devices, through a cash and stock deal approved by the Singapore Stock Exchange (SGX) and Biosensors shareholders.

As a result of the deal, Weigao has become a key Biosensors shareholder and holds two seats on the Company's board of directors. Details can be found in the Investor Relations section of this website.

Coronary artery disease (CAD) is the second-biggest killer in China, accounting for 20% of all deaths in 2009. More than 95% of percutaneous coronary intervention (PCI) procedures, commonly known as coronary angioplasty, use a DES. Three-quarters of DES are manufactured domestically. The overall China market is currently estimated at close to half a billion US dollars and is expected to continue to grow rapidly in coming years.

"We now have a unique opportunity for Biosensors to become a major player in China's substantial and rapidly growing DES market", commented Biosensors Co-CEO Jack Wang. "In addition to JWMS's current product range, we can use their established distribution network and domestic manufacturing capability to introduce Biosensors product lines in China. With Weigao's active involvement in Biosensors, we also gain access to the resources and expertise of one of China's leading medical device companies".

"The deal is not only good news for Biosensors in China, but also for our other global markets", added Biosensors Co-CEO Jeffrey B. Jump. "It provides us with an additional manufacturing facility to service global demand, as well as giving us access to Weigao's complete product range outside China".

#### **For further information, please contact:**

Corporate Communications

Richard Kenyon  
+44 7831569940

[r.kenyon@biosensors.com](mailto:r.kenyon@biosensors.com)

Investor Relations

Wong Teck Yenn  
+65 6213 5708

[ty.wong@biosensors.com](mailto:ty.wong@biosensors.com)